Impact of genomic risk factors on survival after haematopoietic stem cell transplantation for patients with acute leukaemia   

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023698%3A_____%2F16%3AN0000023" target="_blank" >RIV/00023698:_____/16:N0000023 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/16:10333456 RIV/00216208:11120/16:43912496 RIV/00064203:_____/16:10333456

Výsledek na webu

<a href="http://dx.doi.org/10.1111/iji.12295" target="_blank" >http://dx.doi.org/10.1111/iji.12295</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/iji.12295" target="_blank" >10.1111/iji.12295</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Impact of genomic risk factors on survival after haematopoietic stem cell transplantation for patients with acute leukaemia   

Popis výsledku v původním jazyce

The EBMT risk score is an established tool successfully used in the prognosis of survival post-HSCT and is applicable for a range of haematological disorders. One of its main advantages is that score generation involves summation of clinical parameters that are available pretransplant. However, the EBMT risk score is recognized as not being optimal. Previous analyses, involving patients with various diagnoses, have shown that non-HLA gene polymorphisms influence outcome after allogeneic HSCT. This study is novel as it focuses only on patients having acute leukaemia (N = 458) and attempts to demonstrate how non-HLA gene polymorphisms can be added to the EBMT risk score in a Cox regression model to improve prognostic ability for overall survival. The results of the study found that three genetic factors improved EBMT risk score.

Název v anglickém jazyce

Impact of genomic risk factors on survival after haematopoietic stem cell transplantation for patients with acute leukaemia   

Popis výsledku anglicky

The EBMT risk score is an established tool successfully used in the prognosis of survival post-HSCT and is applicable for a range of haematological disorders. One of its main advantages is that score generation involves summation of clinical parameters that are available pretransplant. However, the EBMT risk score is recognized as not being optimal. Previous analyses, involving patients with various diagnoses, have shown that non-HLA gene polymorphisms influence outcome after allogeneic HSCT. This study is novel as it focuses only on patients having acute leukaemia (N = 458) and attempts to demonstrate how non-HLA gene polymorphisms can be added to the EBMT risk score in a Cox regression model to improve prognostic ability for overall survival. The results of the study found that three genetic factors improved EBMT risk score.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

—

Návaznosti

R - Projekt Ramcoveho programu EK

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Immunogenetics  

ISSN

1744-3121

e-ISSN

—

Svazek periodika

43

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

404-412

Kód UT WoS článku

000393312700007

EID výsledku v databázi Scopus

2-s2.0-84995810988